Concordia Healthcare Corp. to Host First Quarter 2015 Results Conference Call

TORONTO, April 24, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or "the Company") (TSX: CXR) (OTCQX: CHEHF), today announced it will release its first quarter 2015 financial results after market close on Thursday, May 14, 2015.

The Company will subsequently hold a conference call on Friday, May 15, 2015, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, Mr. Leith Tessy, Chief Financial Officer, and Mr. Wayne Kreppner, Chief Operating Officer. A question-and-answer session will follow the corporate update.

This call is being webcast and can be accessed from the Concordia website at www.concordiarx.com or by going to:

http://event.on24.com/r.htm?e=987328&s=1&k=7C6A452766458FDC8F49AD827DFAECAF

An archived replay of the webcast will be available for one year.

About Concordia

Concordia is a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs. Concordia's legacy pharmaceutical division, Concordia Pharmaceuticals Inc., consists of 23 products including Nilandron®, for the treatment of metastatic prostate cancer; Dibenzyline®, for the treatment of pheochromocytoma; Lanoxin®, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil®, for the treatment of lupus and rheumatoid arthritis, Donnatal® for the treatment of irritable bowel syndrome and Zonegran® (zonisamide) for treatment of partial seizures in adults with epilepsy. 

Concordia's specialty healthcare distribution (SHD) division, Complete Medical Homecare, distributes medical supplies targeting diabetes and related conditions. 

Concordia's orphan drugs division, Concordia Laboratories Inc., manufactures PHOTOFRIN®. PHOTOFRIN® is marketed by Pinnacle Biologics, Inc. in the United States.

Concordia operates out of facilities in Oakville, Ontario; Bridgetown, Barbados; Kansas City, Missouri; Chicago, Illinois and Charlottesville, Virginia.

SOURCE Concordia Healthcare Corp.